Liposomes as Nanovaccine Delivery Systems
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Since the discovery of liposomes by Alec Bangham in mid-1960s, these phospholipid vesicles have been widely used as pharmaceutical carriers. Liposomes have been extensively studied in the vaccine delivery field as a carrier and an immune stimulating agent. Liposomes are usually formulated as nanoparticles, mimicking the properties of pathogens, and have the ability to induce humoral and cell-mediated immune responses. In this review, we focused on modern nanotechnology-based approaches for the improvement of liposomal vaccine delivery systems. Topics such as size-dependent uptake, processing and activation of antigen presenting cells, targeting liposomes and route of administration are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · cited 1×
“Since their discovery half a century ago, liposomes have been one of the most studied nanocarriers in the pharmaceutical industry [1].”
BackgroundAhsan, F. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00549-1 · Cited by 570 · cited 1×
“Liposomes have been a particularly promising method to overcome poor immunogenicity of subunit vaccines by acting as an immunestimulatory agent (adjuvant) and also allow targeted delivery of antigen by surface modification while maintaining general safety profile of liposomes [20, 27].”
MethodRecent progress in adjuvant discovery for peptide-based subunit vaccines
Azmi, F., Ahmad Fuaad, A. A. H., Skwarczynski, M., & Toth, I. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27332 · Cited by 239 · cited 1×
“water emulsions (M59 and AS03) for influenza vaccines in Europe, (b) monophosporyl lipid A adsorbed to alum (AS04) for hepatitis B vaccine, and human papillomavirus, and (c) virosomes used for hepatitis A and influenza vaccines in [41, 42].”
Black, M., Trent, A., Tirrell, M., & Olive, C. (2010) · Expert Review of Vaccines · doi:10.1586/erv.09.160 · Cited by 203
Chono, S., Tanino, T., Seki, T., & Morimoto, K. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.011 · Cited by 164 · cited 1×
“This includes asthma, chronic obstructive pulmonary disease (COPD), atherosclerosis, cancer, [13-15] and pathogenic infections such as tuberculosis [16], human immunodeficiency virus (HIV), leishmaniasis etc.”
Background
Cited by
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Peptide-based synthetic vaccines
Skwarczynski, M., & Toth, I. (2016) · Chemical Science · doi:10.1039/c5sc03892h · Cited by 596
Current applications of nanoparticles in infectious diseases
Zazo, H., Colino, C. I., & Lanao, J. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.008 · Cited by 434
Metadata
- Authors
- Ghaffar, K., Giddam, A., Zaman, M., Skwarczynski, M., & Toth, I.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-03-29
- Volume
- 14
- Issue
- 9
- Pages
- 1194-1208
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2109482774
- Cited by
- 101
- References
- 6
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liposomes as Nanovaccine Delivery Systems. https://app.cochat.ai/papers/10.2174/1568026614666140329232757
- The paper
- Ghaffar, K., Giddam, A., Zaman, M., Skwarczynski, M., & Toth, I. (2014). Liposomes as Nanovaccine Delivery Systems. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/1568026614666140329232757
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.